Trends and issues in oncology costs
Authors:
- Julieta F ScaloJSJulieta F Scalo
- Karen L RascatiKRKaren L Rascati
- 13 December 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 14 (1) , 35-44
Abstract
Approximately 18% of US gross domestic product is spent on healthcare and 5% of that is for cancer care. With rapidly increasing oncologic drug prices, growth in cancer spending will likely far outpace overall healthcare spending growth. Developing cost-saving strategies is imperative, but economizing must not compromise patients' well-being. Providing quality care at the most economical price is the main aim. This article summarizes trends in rising cancer costs, and reviews cost-management strategies, including those proposed in the Affordable Care Act. Many programs economize by correcting inefficiencies, preventing therapeutic failures and eliminating errors. Process improvement is important, but in oncology, medications substantially drive costs. Identifying the most effective and economical treatments requires cost-effectiveness research. At the current pace, the US payers cannot continue to afford increasing costs for cancer treatments. Research on maximizing patient outcomes for reasonable costs is essential. More analyses of quality of life assessment and cost-effectiveness can support future decisions about cancer care.Keywords
This publication has 75 references indexed in Scilit:
- Tying Payment Incentives to Quality MeasurementJournal of Oncology Practice, 2013
- Key issues in the design of pay for performance programsThe European Journal of Health Economics, 2011
- Quality of care in patients with bladder cancerCancer, 2011
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011
- Defining and Measuring the Patient-Centered Medical HomeJournal of General Internal Medicine, 2010
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion QuestionJNCI: Journal of the National Cancer Institute, 2009
- Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug PricingJournal of Clinical Oncology, 2009
- Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?Journal of Clinical Oncology, 2008
- Evaluation of Trends in the Cost of Initial Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2008
- Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphomaLeukemia & Lymphoma, 2008